Sugi Predict

Sugi Predict / Targets / PKN1

PKN1

Serine/threonine-protein kinase N1 · Q16512 · PKN1 on Sugi Atlas →

28,419 patent compounds predicted against PKN1, 20,557 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Ucn-01 Ucn-01 (SCHEMBL259162) 1.00 4/20
SCHEMBL316190 SCHEMBL316190 0.60 4/20
SCHEMBL206244 SCHEMBL206244 0.52 4/20
SCHEMBL189169 SCHEMBL189169 0.52 3/20
Hydroxyfasudil Hydroxyfasudil (SCHEMBL123699) 1.00 2/20
Uprosertib Uprosertib (SCHEMBL168584) 1.00 2/20
Afuresertib Afuresertib (SCHEMBL187686) 1.00 2/20
Tofacitinib Tofacitinib (SCHEMBL322753) 1.00 2/20
Capivasertib Capivasertib (SCHEMBL390243) 1.00 2/20
Capivasertib Capivasertib (SCHEMBL390244) 1.00 2/20
Capivasertib Capivasertib (SCHEMBL391382) 1.00 2/20
SCHEMBL98692 SCHEMBL98692 0.92 2/20
SCHEMBL386619 SCHEMBL386619 0.90 2/20
SCHEMBL386620 SCHEMBL386620 0.90 2/20
SCHEMBL390401 SCHEMBL390401 0.90 2/20
SCHEMBL391567 SCHEMBL391567 0.87 2/20
SCHEMBL391511 SCHEMBL391511 0.84 2/20
SCHEMBL391512 SCHEMBL391512 0.84 2/20
SCHEMBL386843 SCHEMBL386843 0.84 2/20
SCHEMBL386844 SCHEMBL386844 0.84 2/20

Clinical trials — most relevant to PKN1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Trial of Metformin for Colorectal Cancer Risk Reduction for History of Colorectal Adenomas and Elevated BMI PHASE2COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety PHASE2COMPLETED
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy PHASE2RECRUITING
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) nanRECRUITING
HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors) nanUNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Pediatric Cardiomyopathy Mutation Analysis nanRECRUITING
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies nanENROLLING_BY_INVITATION
PKP2-ACM Natural History Study nanRECRUITING
Fluorodeoxyglucose Positron Emission Tomography (FDG PET) Findings in Patients With Phenylketonuria Before and After KUVAN Therapy nanCOMPLETED
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders nanCOMPLETED
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction nanCOMPLETED
Pyruvate Kinase Deficiency Epidemiological Study (PIECE) nanCOMPLETED
The PAH Platform for Deep Phenotyping in Korean Subjects nanUNKNOWN
ProGRP, CgA, NSE and TUM2-PK in in Patients With Neuroendocrine Tumors nanUNKNOWN
Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex nanCOMPLETED
Study of Proteus Syndrome and Related Congenital Disorders nanRECRUITING
PLIN1 Variants in Precocious ACS (SCAPLIN) nanUNKNOWN
Biomarkers in SCOTland CardiomyopatHy Registry (Bio-SCOTCH) nanRECRUITING
Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy nanCOMPLETED
Protein Intake and Step Reduction in Older Adults nanCOMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING
Identification of Novel Targetable Kinases in SR-a GvHD nanCOMPLETED
Natural History Study of Mitochondrial Myopathy nanRECRUITING
Heart and Skeletal Muscle Problems in Neuroacanthocytosis nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PKN1 binder may also engage these)

ProteinNameSimilarity
A1A4I4 — 1.000 A1A4I4 →
P70268 — 1.000 P70268 →
Q63433 — 1.000 Q63433 →
PKN3 Serine/threonine-protein kinase N3 0.990 landscape →
Q8K045 — 0.989 Q8K045 →
MAP4K2 Mitogen-activated protein kinase kinase kinase kinase 2 0.981 landscape →
A4D2P6 — 0.980 A4D2P6 →
Q9Z268 — 0.979 Q9Z268 →
Q6ZT62 — 0.979 Q6ZT62 →
Q61161 — 0.979 Q61161 →
O62683 — 0.978 O62683 →
Q3MII6 — 0.977 Q3MII6 →
B2DCZ9 — 0.977 B2DCZ9 →
Q0QWG9 — 0.977 Q0QWG9 →
Q9BST9 — 0.977 Q9BST9 →
O95294 — 0.976 O95294 →
O35465 — 0.976 O35465 →
Q9HA65 — 0.975 Q9HA65 →
P97492 — 0.975 P97492 →
Q8BY35 — 0.975 Q8BY35 →
Q3B7U9 — 0.975 Q3B7U9 →
Q66T02 — 0.975 Q66T02 →
Q8BWW9 — 0.975 Q8BWW9 →
Q8NEG4 — 0.975 Q8NEG4 →
Q6PFQ7 — 0.975 Q6PFQ7 →
O95049 — 0.974 O95049 →
O43566 — 0.974 O43566 →
O43374 — 0.974 O43374 →
Q9JLG8 — 0.974 Q9JLG8 →
Q8C190 — 0.974 Q8C190 →